NCT05494697 2025-10-14
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
AIM ImmunoTech Inc.
Phase 2 Suspended
AIM ImmunoTech Inc.
Ability Pharmaceuticals SL
NextPoint Therapeutics, Inc.
Envita Medical Center, Inc.
CMED HIFU Development Corporation
Novacea